Meticulous Research®, a leading market research firm, has published a new report titled, ‘Microbubbles/Ultrasound Contrast Agents Market by Application (Diagnostic Imaging [Cardiovascular, Renal, Abdominal, Breast], Therapeutics), Type (Lipid, Protein, Polymer), End User (Hospitals & Clinics, Diagnostic Laboratories) - Global Forecast to 2030.’

Download free sample report here: https://www.meticulousresearch.com/download-sample-report/cp_id=3732

According to the report, the microbubbles/ultrasound contrast agents market is projected to reach $1.95 billion by 2030, growing at a CAGR of 15.2% from 2023 to 2030. Several factors are driving this growth, including the aging global population, the increasing prevalence of chronic diseases, advances in ultrasound imaging technology, high demand for image- and diagnostics-guided procedures, and favorable reimbursement policies for contrast-enhanced procedures. Additionally, growing research activities related to microbubbles/ultrasound contrast agents offer significant growth opportunities. However, the complexity involved in contrast-enhanced ultrasound (CEUS) procedures may limit the market's expansion to some extent.

  • Key Players

Prominent companies profiled in this report include Lantheus Holdings, Inc. (U.S.), GE HealthCare Technologies Inc. (U.S.), Bracco S.p.A. (Italy), Bristol-Myers Squibb Company (U.S.), Daiichi Sankyo Company, Limited (Japan), nanoPET Pharma GmbH (Germany), Leriva (Greece), Siemens Healthineers AG (Germany), Bayer AG (Germany), and Fujifilm Holdings Corporation (Japan).

Browse in depth: https://www.meticulousresearch.com/product/microbubbles-ultrasound-contrast-agents-market-3732

  • Microbubbles/Ultrasound Contrast Agents Market: Future Outlook

The microbubbles/ultrasound contrast agents market is segmented by type (lipid, protein, and polymer microbubbles), application (diagnostic imaging [cardiovascular, renal, abdominal, breast, and other diagnostics imaging applications], and therapeutic applications), end user (hospitals & clinics, diagnostic laboratories, and others), and geography (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa).

  • Type Segment: In 2023, the lipid microbubbles segment is expected to dominate the market. Lipid-based microbubbles offer unique properties for both diagnostic imaging and drug delivery applications, which has led to increased research and expansion into therapeutic areas such as tumor-targeted therapy, brain-targeted therapy, and immunotherapy.

Download request sample report here: https://www.meticulousresearch.com/request-sample-report/cp_id=3732

  • Application Segment: The market is divided into diagnostic imaging and therapeutic applications. In 2023, diagnostic imaging is projected to account for the largest market share, driven by growing demand for radiation-free and non-invasive diagnostic methods for conditions such as cardiovascular, abdominal, and breast disorders.
  • End User Segment: In 2023, hospitals & clinics are expected to hold the largest market share. This dominance is attributed to the rising number of hospital admissions, increasing healthcare spending, expanding healthcare infrastructure in emerging economies, and the established infrastructure in developed regions.
  • Geographic Review

Geographically, North America is projected to account for the largest share of the microbubbles/ultrasound contrast agents market in 2023. Factors contributing to this lead include the rising demand for imaging and diagnostics-guided procedures, the presence of major industry players, and the availability of advanced healthcare systems in the region.

The report highlights the potential for robust growth in the microbubbles/ultrasound contrast agents market, with innovation and expansion across applications and geographies set to fuel market demand through 2030.

Quick buy: https://www.meticulousresearch.com/Checkout/42178959

Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research